Improving adherence to HIV prevention medication for men who have sex with men in South Africa
Official title: The Role of Cognitive Biases in the Decision to Request, Offer, Accept and Continue on PrEP From a Health Care Provider and Patient Perspective (Men Who Have Sex With Men)
Run by Boston University · NCT06476847 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new way to help men who have sex with men in South Africa stick to their HIV prevention medication by using reminders and planning tools to see if it makes a difference.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 140 (estimated) |
| Sponsor | Boston University Academic / other |
| Locations | 3 sites (Boston, Massachusetts and 2 other locations) |
| Trial ID | NCT06476847 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are men who have sex with men, are initiating PrEP, and have not used PrEP in the past 12 months.
✕Probably not a fit
Patients who are currently on PrEP or have used it within the last year may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates a behavioral economics-informed intervention aimed at increasing persistence on pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in South Africa. Participants will be randomized to receive either standard care or an intervention package that includes reminders, commitment pledges, and planning prompts to enhance their adherence to PrEP. The study aims to assess the feasibility and acceptability of this approach in a routine healthcare setting, with the ultimate goal of informing a larger effectiveness trial.
Why it matters
Potential benefit: If successful, this intervention could significantly improve adherence to PrEP, thereby reducing the incidence of HIV infections among MSM.
How similar studies have gone: Other studies have shown promise in using behavioral economics strategies to improve medication adherence, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Not currently on pre exposure prophylaxis (PrEP); no PrEP within the last 12 months * Initiating PrEP on the date of enrolment * Access to a mobile phone * Willing and able to provide written informed consent in English Exclusion Criteria: * PrEP status unknown * Previous PrEP experience within the last year (12 months from enrolment)
Where it's running
-
The Aurum POP INN Clinic
Pretoria, Gauteng, South Africa Recruiting -
The Ivan Tom's Centre for Men's Health
Cape Town, Western Cape, South Africa Recruiting -
Boston Univeristy School ofPublic Health, Global Health
Boston, Massachusetts, United States Not yet recruiting
Study contacts
- Principal investigator: Lawrence C Long, PhD MCom — Boston University School of Public Health,Global Health
- Study coordinator: Lawrence C Long, PhD MCom
- Email: lclong@bu.edu
- Phone: 617 358 3122
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.